Search Result
Results for "
aggregate
" in MedChemExpress (MCE) Product Catalog:
50
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-160116
-
|
|
α-synuclein
|
Neurological Disease
|
|
α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease .
|
-
-
- HY-113950
-
|
|
Transthyretin (TTR)
|
Neurological Disease
|
|
Dichlorophenyl-ABA is an inhibitor of transthyretin (TTR) amyloid fibril formation, inhibiting aggregate formation in more than 80% in TTR L55P-expressing cells .
|
-
-
- HY-122958
-
|
|
α-synuclein
|
Neurological Disease
|
|
Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .
|
-
-
- HY-167001
-
|
PLGA10000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA10000-PEG1000-VS (PLGA10000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167005
-
|
PLGA10000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA10000-PEG2000-VS (PLGA10000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167006
-
|
PLGA10000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA10000-PEG3000-VS (PLGA10000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167007
-
|
PLGA10000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA10000-PEG5000-VS (PLGA10000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167008
-
|
PLGA1000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA1000-PEG1000-VS (PLGA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167009
-
|
PLGA1000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA1000-PEG2000-VS (PLGA1000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167010
-
|
PLGA1000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA1000-PEG3000-VS (PLGA1000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167013
-
|
PLGA1000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA1000-PEG5000-VS (PLGA1000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167014
-
|
PLGA2000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA2000-PEG1000-VS (PLGA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167017
-
|
PLGA2000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA2000-PEG2000-VS (PLGA2000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167018
-
|
PLGA2000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA2000-PEG3000-VS (PLGA2000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167019
-
|
PLGA2000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA2000-PEG5000-VS (PLGA2000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167020
-
|
PLGA3000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA3000-PEG1000-VS (PLGA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167023
-
|
PLGA3000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA3000-PEG2000-VS (PLGA3000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167026
-
|
PLGA3000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA3000-PEG3000-VS (PLGA3000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167027
-
|
PLGA3000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA3000-PEG5000-VS (PLGA3000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167029
-
|
PLGA4000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA4000-PEG1000-VS (PLGA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167030
-
|
PLGA4000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA4000-PEG2000-VS (PLGA4000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167032
-
|
PLGA4000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA4000-PEG3000-VS (PLGA4000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167033
-
|
PLGA4000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA4000-PEG5000-VS (PLGA4000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167034
-
|
PLGA5000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA5000-PEG1000-VS (PLGA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167035
-
|
PLGA5000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA5000-PEG2000-VS (PLGA5000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167037
-
|
PLGA5000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA5000-PEG3000-VS (PLGA5000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167038
-
|
PLGA5000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA5000-PEG5000-VS (PLGA5000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167039
-
|
PLLA5000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG5000-VS (PLLA5000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167040
-
|
PLLA10000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-VS (PLLA10000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167041
-
|
PLLA5000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG3000-VS (PLLA5000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167042
-
|
PLLA10000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG2000-VS (PLLA10000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167043
-
|
PLLA10000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG3000-VS (PLLA10000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167044
-
|
PLLA5000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG2000-VS (PLLA5000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167045
-
|
PLLA10000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG5000-VS (PLLA10000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167046
-
|
PLLA1000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-VS (PLLA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167047
-
|
PLLA5000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-VS (PLLA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167048
-
|
PLLA1000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG2000-VS (PLLA1000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167049
-
|
PLLA4000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG5000-VS (PLLA4000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167050
-
|
PLLA1000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG3000-VS (PLLA1000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167051
-
|
PLLA1000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG5000-VS (PLLA1000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167052
-
|
PLLA2000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-VS (PLLA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167053
-
|
PLLA4000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG3000-VS (PLLA4000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167054
-
|
PLLA2000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG2000-VS (PLLA2000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167055
-
|
PLLA4000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG2000-VS (PLLA4000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167056
-
|
PLLA4000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-VS (PLLA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167057
-
|
PLLA3000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG5000-VS (PLLA3000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167058
-
|
PLLA3000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG3000-VS (PLLA3000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167059
-
|
PLLA3000-PEG2000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG2000-VS (PLLA3000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167060
-
|
PLLA3000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-VS (PLLA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167061
-
|
PLLA2000-PEG5000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG5000-VS (PLLA2000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167062
-
|
PLLA2000-PEG3000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG3000-VS (PLLA2000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-112636
-
|
|
Amyloid-β
|
Others
|
|
Astrophloxine is a fluorescent imaging probe capable of targeting antiparallel dimers. Astrophloxine can be used to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of Alzheimer's disease (AD) mice .
|
-
- HY-161458
-
|
|
GSK-3
Tau Protein
|
Neurological Disease
|
|
GSK-3β inhibitor 16 (compound 7c) is a GSK-3β inhibitor with the IC50 of 4.68 nM. GSK-3β inhibitor 16 decreases Tau hyperphosphorylated aggregate and alleviates cognitive impairments in the Scopolamin (HY-N0296)-induced model in mice .
|
-
- HY-113434B
-
|
(±)-5-HETE
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
5-HETE ((±)-5-HETE), a fatty acid, is a oxidative derivative of Arachidonic acid. 5-HETE is a mixture of 5(S)-HETE and 5(R)-HETE. 5-HETE is a potent aggregating agent that induces the aggregation of neutrophils with an IC50 value of 200 nM .
|
-
- HY-150049
-
|
|
Amyloid-β
|
Neurological Disease
|
|
γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease .
|
-
- HY-150050
-
|
|
Amyloid-β
|
Neurological Disease
|
|
gamma-secretase modulator 5 (compound 22d) is a brain-penetrant gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 60 nM. gamma-secretase modulator 5 can be used in the study of Alzheimer's disease .
|
-
- HY-P1474
-
|
Amyloid β-Protein (22-35)
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P1474A
-
|
Amyloid β-Protein (22-35) (TFA)
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-101855
-
|
Anle138b
|
Amyloid-β
|
Neurological Disease
|
|
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
|
-
- HY-158204
-
|
|
Lipoxygenase
|
Neurological Disease
|
|
CNB-001 is a potent 5-lipoxygenase (5-LOX) inhibitor, decreases 5-LOX expression, and increases proteasome activity. CNB-001 also increases eIF2α phosphorylation and HSP90 and ATF4 levels in Alzheimer's disease transgenic mice, and limits the accumulation of soluble Aβ and ubiquitinated aggregated proteins. CNB-001 maintains the expression of synapse-associated proteins and improves memory. CNB-001 can be used for the research of Alzheimer's disease .
|
-
- HY-139166
-
|
N-Palmitoyl aspartic acid
|
Others
|
Others
|
|
N-Palmitoyl-L-aspartate (N-Palmitoyl aspartic acid) is a chiral compound with properties of the aggregates formed in aqueous solution .
|
-
- HY-151554
-
|
|
Amyloid-β
|
Others
|
|
SQ-3 is a quinoline analogue, displays moderate selectivity for α-syn aggregates (Ki=39.3 nM) over β-amyloid (Aβ) aggregates (Ki=230 nM). [ 18F]SQ3 has basic properties as a lead compound for the development of a useful α-syn imaging probe .
|
-
- HY-W750960
-
|
|
Antibiotic
|
Others
|
|
Biotinylated isoxazole is a biotinylated derivative of Isoxazole (HY-W010649). Biotinylated isoxazole is capable of triggering the formation of aggregates related to RNA granules .
|
-
- HY-134879
-
-
- HY-138643
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein .
|
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
- HY-134880
-
-
- HY-161743
-
|
|
AUTOTACs
Autophagy
|
Cancer
|
|
PBA-1105 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105 increases the autophagic flux of Ub-conjugated aggregates .
|
-
- HY-161744
-
|
|
AUTOTACs
Autophagy
|
Cancer
|
|
PBA-1106 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1106 increases the autophagic flux of Ub-conjugated aggregates .
|
-
- HY-P9967
-
|
BIIB037
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
-
- HY-156842
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice .
|
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
-
- HY-N6806
-
-
- HY-103242
-
|
|
Amyloid-β
|
Neurological Disease
|
|
CRANAD-2 is a near-infrared (NIR) Aβ plaque-specific fluorescent probe. CRANAD 2 penetrates the blood brain barrier and has a high affinity for Aβ aggregates with a Kd of 38 nM .
|
-
- HY-N2092
-
|
|
Bacterial
|
Infection
Cancer
|
|
Atractylodinol, an antimicrobial, is a PRRSV (porcine reproductive and respiratory syndrome virus) inhibitor. Atractylodinol inhibits TGF-β receptor I recycling by binding to vimentin (KD of 454 nM) and inducing the formation of filamentous aggregates .
|
-
- HY-50001
-
|
|
Influenza Virus
|
Infection
|
|
Nucleozin, a potent inhibitor of influenza A virus infection, induces the formation of nucleoprotein (NP) aggregates and antagonizes its nuclear accumulation, leading to cessation of viral replication. Nucleozin impedes influenza A virus replication in vitro with a nanomolar EC50 .
|
-
- HY-N3380
-
|
|
PGE synthase
Interleukin Related
|
Inflammation/Immunology
|
|
Linderaspirone A is a natural compound that can be isolated from the roots of Lindera aggregate. Linderaspirone A shows significant inhibitory effects on the production of prostaglandin E2 (PGE2),TNF-α, and IL-6 .
|
-
- HY-134939
-
|
|
Others
|
Others
|
|
thio-Miltefosine is a modulator of rafts in membrane tissue. Rafts are nanoscale aggregates of different lipids and proteins that profoundly affect cellular function. Thio-Miltefosine modulates membrane phase behavior on cell-derived giant plasma membrane vesicles .
|
-
- HY-15534
-
JC-1
Maximum Cited Publications
115 Publications Verification
CBIC2
|
Fluorescent Dye
|
Others
|
|
JC-1 (CBIC2) is an ideal fluorescent probe widely used to detect mitochondrial membrane potential. JC-1 accumulates in mitochondria in a potential dependent manner and can be used to detect the membrane potential of cells, tissues or purified mitochondria. In normal mitochondria, JC-1 aggregates in the mitochondrial matrix to form a polymer, which emits strong red fluorescence (Ex=488 nm, Em=595 nm); When the mitochondrial membrane potential is low, JC-1 cannot aggregate in the matrix of mitochondria and produce green fluorescence (ex=488 nm, em= 530 nm) .
|
-
- HY-148495
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Carnosine conjugated hyalyronate is a hyaluronic acid derivative functionalized with the dipeptide carnosine (Carnosine, Car) and has the ability to resist Aβ amyloid aggregation. Carnosine conjugated hyalyronate dissolves amyloid fibrils and reduces Aβ-induced toxicity in vitro. The effectiveness of Carnosine conjugated hyalyronate against amyloid aggregation is directly proportional to the Carnosine loading .
|
-
- HY-D0873
-
|
EPPS
|
Amyloid-β
|
Neurological Disease
|
|
HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces Aβ-aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .
|
-
- HY-N1431A
-
|
|
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
|
Tabersonine hydrochloride is an indole alkaloid mainly isolated from Catharanthus roseus. Tabersonine disrupts Aβ(1-42) aggregation and ameliorates Aβ aggregate-induced cytotoxicity. Tabersonine has anti-inflammatory activities and is a potential therapeutic candidate for the treatment of ALI/ARDS .
|
-
- HY-P990078
-
|
LY3372993
|
Amyloid-β
|
Neurological Disease
|
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ that aggregates into amyloid plaques .
|
-
- HY-N1431
-
|
|
Amyloid-β
|
Neurological Disease
Inflammation/Immunology
|
|
Tabersonine is an indole alkaloid mainly isolated from Catharanthus roseus. Tabersonine disrupts Aβ(1-42) aggregation and ameliorates Aβ aggregate-induced cytotoxicity. Tabersonine has anti-inflammatory activities and acts as a potential therapeutic candidate for the treatment of ALI/ARDS .
|
-
- HY-109116A
-
|
Leukomethylene blue dihydrobromide; LMTM dihydrobromide
|
Tau Protein
|
Neurological Disease
|
|
Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide) is a potent inhibitor of TAU protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with TAU proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other TAU related disorders .
|
-
- HY-P10037
-
|
|
Amyloid-β
|
Neurological Disease
|
|
β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD) .
|
-
- HY-157225
-
|
|
α-synuclein
|
Metabolic Disease
|
|
Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .
|
-
- HY-161745
-
|
|
AUTOTACs
p62
Autophagy
|
Cancer
|
|
PBA-1105b is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105b increases the autophagic flux of Ub-conjugated aggregates. PBA-1105b is a drastically longer PEG-based linker than PBA-1105 .
|
-
- HY-103442
-
|
DAPH
|
EGFR
Amyloid-β
|
Neurological Disease
Cancer
|
|
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca 2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .
|
-
- HY-101181
-
|
|
Microtubule/Tubulin
|
Neurological Disease
|
|
THK-5105, an arylquinoline derivative, displays high binding affinity to tau fibrils. THK-5105 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD) brain homogenates. 18F-THK-5105 has the potential to act as a tau imaging PET probe .
|
-
- HY-N2936
-
|
|
Others
|
Others
|
|
Bi-linderone is isolated as racemate from the traditional Chinese medicinal plant Lindera aggregata. Bi-linderone has activity against glucosamine-induced insulin resistance in HepG2 cells at a concentration of 1 μg/mL .
|
-
- HY-P2501
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .
|
-
- HY-101182
-
|
|
Microtubule/Tubulin
|
Neurological Disease
|
|
THK-5117, an arylquinoline derivative, displays high binding affinity to tau fibrils with a Ki of 10.5 nM. THK-5117 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD) brain homogenates. 18F-THK-5117 has the potential to act as a tau imaging PET probe .
|
-
- HY-15917A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
L-Dithiothreitol (DTT) is a reducing agent commonly used in various biochemical applications to break disulfide bonds in proteins, thereby denaturing proteins or preventing the formation of unwanted aggregates. DTT has a unique chemical property that cleaves the sulfur-sulfur bond in the disulfide bond to form a sulfhydryl group. This makes it a useful tool for protein purification, enzyme assays, and protein structure studies.
|
-
- HY-123985
-
|
|
Others
|
Others
|
|
MFN2 agonist-1 (B-A/l) potently stimulates mitochondrial fusion in mitofusin 2 (MFN2)-deficient cells. MFN2 agonist-1 reverses mitochondrial “clumping” (formation of static mitochondrial aggregates) and restores mitochondrial motility in cultured mouse neurons expressing the CMT2A mutant MFN2 T105M.
|
-
- HY-163057
-
|
|
Others
|
Inflammation/Immunology
|
|
2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline) is a trivalent hapten. 2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline) can aggregate with monoclonal anti-2,4-DNP IgG (IgGDNP) .
|
-
- HY-136780
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SEN177 is a potent glutaminyl cyclase (QPCT) inhibitor with an IC50 of 0.013μM for glutaminyl-peptide cyclotransferase-like (QPCTL). SEN177 has a Ki of 20 nM for human glutaminyl cyclase (hQC). SEN177 greatly reduces the early stages of mutant HTT oligomerisation and reduces the percentage of neurons with Q80 aggregates. SEN177 has the potential for Huntington’s disease research .
|
-
- HY-P2260
-
|
|
Autophagy
HIV
|
Infection
|
|
Tat-beclin 1, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of autophagy and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya (CHIKV) or West Nile virus (WNV) .
|
-
- HY-143218
-
TPE-MI
2 Publications Verification
Tetraphenylethene maleimide
|
Huntingtin
Parasite
|
Neurological Disease
|
|
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
|
-
- HY-D1684
-
|
|
Amyloid-β
|
Neurological Disease
|
|
DCDAPH (Compound 2c) is a novel smart NIRF probe for detection of β-amyloid (Aβ) plaques (λex/λem=597/665 nm in PBS). DCDAPH shows high affinity for Aβ aggregates (Ki=37 nM, Kd=27 nM). DCDAPH shows good blood brain barrier permeation and can meet most of the requirements for the detection of Aβ plaques both in vitro and in vivo .
|
-
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
-
- HY-155021
-
|
|
PROTACs
α-synuclein
|
Neurological Disease
|
|
PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of α-synuclein aggregates, with an DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research .
|
-
- HY-P2260A
-
|
|
Autophagy
HIV
|
Infection
|
|
Tat-beclin 1 TFA, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of autophagy and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2). Tat-beclin 1 TFA decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya (CHIKV) or West Nile virus (WNV) .
|
-
- HY-157382
-
|
|
Cholinesterase (ChE)
Amyloid-β
MMP
|
Neurological Disease
|
|
AChE-IN-51 (compound 8C) is an orally active, non-competitive inhibitor of AChE and BChE (IC50: 84 nM, 97 nM). It also inhibits MMP-2 and amyloid Aβ1-42 aggregates (IC50: 724 nM, 302 nM). AChE-IN-51 has low cytotoxicity and in silico predicted blood-brain barrier permeability. Can be used for research on diseases such as Alzheimer's disease (AD) .
|
-
- HY-161723
-
|
|
Dopamine Transporter
CDK
|
Neurological Disease
|
|
LH2-051 is a lysosome-enhancing lead compound, which promotes the lysosome biogenesis and the Aβ aggregate clearance through dopamine transporter-cyclin-dependent kinase 9-transcription factor EB (DAT-CDK9-TFEB) pathway. LH2-051 exhibits good pharmacokinetic characteristics in mouse models. LH2-051 is potential for ameliorating Aleheimer’s Disease .
|
-
- HY-145785
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
|
-
- HY-P5906
-
|
Citrullinated Aβ (1-40); Citrullinated Aβ40
|
Amyloid-β
|
Neurological Disease
|
|
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .
|
-
- HY-145785A
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 TFA has the potential for the research of cancer diseases .
|
-
- HY-149763
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
|
-
- HY-128892
-
EN6
3 Publications Verification
|
Autophagy
|
Neurological Disease
|
|
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
|
-
- HY-149764
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
|
-
- HY-147659
-
|
|
Cholinesterase (ChE)
Beta-secretase
ROS Kinase
|
Neurological Disease
|
|
AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential .
|
-
- HY-147658
-
|
|
Cholinesterase (ChE)
Beta-secretase
ROS Kinase
|
Neurological Disease
|
|
AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential .
|
-
- HY-P2260B
-
|
|
HIV
|
Infection
|
|
Tat-beclin 1 scrambled is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus .
|
-
- HY-P2260C
-
|
|
HIV
|
Infection
|
|
Tat-beclin 1 scrambled TFA is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus .
|
-
- HY-125172
-
|
Polyglutamine Aggregation inhibitor III
|
Others
|
Others
|
|
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
|
-
- HY-105321
-
|
PBT 2
|
Bacterial
|
Neurological Disease
|
|
PBT 1033 (PBT 2) is an orally active copper/zinc ionophore. PBT 1033 restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .
|
-
- HY-105321A
-
|
PBT 2 hydrochloride
|
Bacterial
|
Neurological Disease
|
|
PBT 1033 hydrochloride is an orally active copper/zinc ionophore. PBT 1033 hydrochloride restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .
|
-
- HY-149430
-
|
|
Amyloid-β
|
Neurological Disease
|
|
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .
|
-
-
-
HY-L0124V
-
|
|
13,082 compounds
|
|
The basic requirements for the compounds that are supposed to penetrate the blood-brain barrier are somewhat different from those for the majority of drug discovery projects. Alongside the known problem with delivery of the large and non-polar compounds and their penetrability through the cell membrane, the other issue arises as well: small and polar compounds are not able to pass the Blood-Brain Barrier. Chemspace CNS-focused library comprises quite small, non-polar compounds that are also free from PAINS/toxic fragments and aggregators.
|
-
-
HY-L085
-
|
|
1,466 compounds
|
|
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.
MCE offers a unique collection of 1,466 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.
|
| Cat. No. |
Product Name |
Type |
-
- HY-15534
-
|
CBIC2
|
Fluorescent Dyes/Probes
|
|
JC-1 (CBIC2) is an ideal fluorescent probe widely used to detect mitochondrial membrane potential. JC-1 accumulates in mitochondria in a potential dependent manner and can be used to detect the membrane potential of cells, tissues or purified mitochondria. In normal mitochondria, JC-1 aggregates in the mitochondrial matrix to form a polymer, which emits strong red fluorescence (Ex=488 nm, Em=595 nm); When the mitochondrial membrane potential is low, JC-1 cannot aggregate in the matrix of mitochondria and produce green fluorescence (ex=488 nm, em= 530 nm) .
|
-
- HY-143218
-
TPE-MI
2 Publications Verification
Tetraphenylethene maleimide
|
Fluorescent Dyes/Probes
|
|
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
|
-
- HY-D1684
-
|
|
Fluorescent Dyes/Probes
|
|
DCDAPH (Compound 2c) is a novel smart NIRF probe for detection of β-amyloid (Aβ) plaques (λex/λem=597/665 nm in PBS). DCDAPH shows high affinity for Aβ aggregates (Ki=37 nM, Kd=27 nM). DCDAPH shows good blood brain barrier permeation and can meet most of the requirements for the detection of Aβ plaques both in vitro and in vivo .
|
| Cat. No. |
Product Name |
Type |
-
- HY-167001
-
|
PLGA10000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA10000-PEG1000-VS (PLGA10000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167005
-
|
PLGA10000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLGA10000-PEG2000-VS (PLGA10000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167006
-
|
PLGA10000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLGA10000-PEG3000-VS (PLGA10000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167007
-
|
PLGA10000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLGA10000-PEG5000-VS (PLGA10000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167008
-
|
PLGA1000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA1000-PEG1000-VS (PLGA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167009
-
|
PLGA1000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLGA1000-PEG2000-VS (PLGA1000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167010
-
|
PLGA1000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLGA1000-PEG3000-VS (PLGA1000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167013
-
|
PLGA1000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLGA1000-PEG5000-VS (PLGA1000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167014
-
|
PLGA2000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA2000-PEG1000-VS (PLGA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167017
-
|
PLGA2000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLGA2000-PEG2000-VS (PLGA2000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167018
-
|
PLGA2000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLGA2000-PEG3000-VS (PLGA2000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167019
-
|
PLGA2000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLGA2000-PEG5000-VS (PLGA2000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167020
-
|
PLGA3000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA3000-PEG1000-VS (PLGA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167023
-
|
PLGA3000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLGA3000-PEG2000-VS (PLGA3000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167026
-
|
PLGA3000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLGA3000-PEG3000-VS (PLGA3000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167027
-
|
PLGA3000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLGA3000-PEG5000-VS (PLGA3000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167029
-
|
PLGA4000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA4000-PEG1000-VS (PLGA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167030
-
|
PLGA4000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLGA4000-PEG2000-VS (PLGA4000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167032
-
|
PLGA4000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLGA4000-PEG3000-VS (PLGA4000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167033
-
|
PLGA4000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLGA4000-PEG5000-VS (PLGA4000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167034
-
|
PLGA5000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA5000-PEG1000-VS (PLGA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167035
-
|
PLGA5000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLGA5000-PEG2000-VS (PLGA5000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167037
-
|
PLGA5000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLGA5000-PEG3000-VS (PLGA5000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167038
-
|
PLGA5000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLGA5000-PEG5000-VS (PLGA5000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167039
-
|
PLLA5000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLLA5000-PEG5000-VS (PLLA5000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167040
-
|
PLLA10000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA10000-PEG1000-VS (PLLA10000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167041
-
|
PLLA5000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLLA5000-PEG3000-VS (PLLA5000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167042
-
|
PLLA10000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLLA10000-PEG2000-VS (PLLA10000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167043
-
|
PLLA10000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLLA10000-PEG3000-VS (PLLA10000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167044
-
|
PLLA5000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLLA5000-PEG2000-VS (PLLA5000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167045
-
|
PLLA10000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLLA10000-PEG5000-VS (PLLA10000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167046
-
|
PLLA1000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA1000-PEG1000-VS (PLLA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167047
-
|
PLLA5000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA5000-PEG1000-VS (PLLA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167048
-
|
PLLA1000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLLA1000-PEG2000-VS (PLLA1000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167049
-
|
PLLA4000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLLA4000-PEG5000-VS (PLLA4000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167050
-
|
PLLA1000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLLA1000-PEG3000-VS (PLLA1000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167051
-
|
PLLA1000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLLA1000-PEG5000-VS (PLLA1000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167052
-
|
PLLA2000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA2000-PEG1000-VS (PLLA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167053
-
|
PLLA4000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLLA4000-PEG3000-VS (PLLA4000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167054
-
|
PLLA2000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLLA2000-PEG2000-VS (PLLA2000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167055
-
|
PLLA4000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLLA4000-PEG2000-VS (PLLA4000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167056
-
|
PLLA4000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA4000-PEG1000-VS (PLLA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167057
-
|
PLLA3000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLLA3000-PEG5000-VS (PLLA3000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167058
-
|
PLLA3000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLLA3000-PEG3000-VS (PLLA3000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167059
-
|
PLLA3000-PEG2000-Vinylsulfone
|
Drug Delivery
|
|
PLLA3000-PEG2000-VS (PLLA3000-PEG2000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167060
-
|
PLLA3000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA3000-PEG1000-VS (PLLA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167061
-
|
PLLA2000-PEG5000-Vinylsulfone
|
Drug Delivery
|
|
PLLA2000-PEG5000-VS (PLLA2000-PEG5000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167062
-
|
PLLA2000-PEG3000-Vinylsulfone
|
Drug Delivery
|
|
PLLA2000-PEG3000-VS (PLLA2000-PEG3000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-D0873
-
|
EPPS
|
Buffer Reagents
|
|
HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces Aβ-aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .
|
-
- HY-15917A
-
|
|
Carbohydrates
|
|
L-Dithiothreitol (DTT) is a reducing agent commonly used in various biochemical applications to break disulfide bonds in proteins, thereby denaturing proteins or preventing the formation of unwanted aggregates. DTT has a unique chemical property that cleaves the sulfur-sulfur bond in the disulfide bond to form a sulfhydryl group. This makes it a useful tool for protein purification, enzyme assays, and protein structure studies.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1474A
-
|
Amyloid β-Protein (22-35) (TFA)
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P0306
-
|
Heparin Binding Peptide
|
Peptides
|
Cardiovascular Disease
|
|
Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells .
|
-
- HY-P2260
-
|
|
Autophagy
HIV
|
Infection
|
|
Tat-beclin 1, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of autophagy and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya (CHIKV) or West Nile virus (WNV) .
|
-
- HY-P1474
-
|
Amyloid β-Protein (22-35)
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P4844
-
|
|
Peptides
|
Others
|
|
Ac-Phe-Phe-OH is a negatively charged analogue of the diphenylalanine peptide that forms large aggregates when combined with the NH2-Phe-Phe-OH peptide .
|
-
- HY-P10037
-
|
|
Amyloid-β
|
Neurological Disease
|
|
β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD) .
|
-
- HY-P2501
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .
|
-
- HY-P0306A
-
|
Heparin Binding Peptide TFA
|
Peptides
|
Cardiovascular Disease
|
|
Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells .
|
-
- HY-P2260A
-
|
|
Autophagy
HIV
|
Infection
|
|
Tat-beclin 1 TFA, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of autophagy and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2). Tat-beclin 1 TFA decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya (CHIKV) or West Nile virus (WNV) .
|
-
- HY-P5906
-
|
Citrullinated Aβ (1-40); Citrullinated Aβ40
|
Amyloid-β
|
Neurological Disease
|
|
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .
|
-
- HY-P5331
-
|
|
Peptides
|
Others
|
|
[Asn23]-beta-Amyloid (1-42), iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
|
-
- HY-P5365
-
|
|
Peptides
|
Others
|
|
[Asn23] β-Amyloid (1-40), Iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
|
-
- HY-P2260B
-
|
|
HIV
|
Infection
|
|
Tat-beclin 1 scrambled is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus .
|
-
- HY-P2260C
-
|
|
HIV
|
Infection
|
|
Tat-beclin 1 scrambled TFA is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
- HY-P9967
-
|
BIIB037
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
-
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
-
- HY-P990078
-
|
LY3372993
|
Amyloid-β
|
Neurological Disease
|
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ that aggregates into amyloid plaques .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
